Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression
Yun‐Cheng Hsieh, Sae Kyung Joo, Bo Kyung Koo, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 2, pp. 388-397.e10
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 5
Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S68-S78
Open Access | Times Cited: 44
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Metabolism (2023) Vol. 147, pp. 155676-155676
Closed Access | Times Cited: 36
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
Pei Chia Eng, Roberta Forlano, Tricia Tan, et al.
JHEP Reports (2023) Vol. 5, Iss. 10, pp. 100835-100835
Open Access | Times Cited: 34
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong‐Kyu Kim, Sung‐Jin Bae, Min Jung Lee, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 987-1001
Open Access | Times Cited: 32
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Simona Cernea
Life (2024) Vol. 14, Iss. 2, pp. 272-272
Open Access | Times Cited: 9
Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease
Guillaume Hénin, Audrey Loumaye, Isabelle Leclercq, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100963-100963
Open Access | Times Cited: 22
Albumin‐myosteatosis gauge as a novel prognostic risk factor in patients with non‐metastatic colorectal cancer
Yerim Kim, Jae‐Hoon Lee, Eun‐Suk Cho, et al.
Journal of Cachexia Sarcopenia and Muscle (2023) Vol. 14, Iss. 2, pp. 860-868
Open Access | Times Cited: 18
Lean nonalcoholic fatty liver disease and sarcopenia
Milian Chen, Ying Cao, Guang Ji, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
Alessandra Musio, Federica Perazza, Laura Leoni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7517-7517
Open Access | Times Cited: 15
RORα–GABP–TFAM axis alleviates myosteatosis with fatty atrophy through reinforcement of mitochondrial capacity
Hyeon‐Ji Kim, Sang‐Heon Lee, Cheolhee Jeong, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 2, pp. 615-630
Open Access | Times Cited: 4
Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Aditya Viswanath, Sherouk Fouda, Cornelius James Fernandez, et al.
World Journal of Hepatology (2024) Vol. 16, Iss. 2, pp. 152-163
Open Access | Times Cited: 4
Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis
Wen Zhang, Shuyue Tuo, Qiuju Ran, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis
Yongjuan Wu, Guangyuan Cheng, Jun Han, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy
Xiaoping Yi, Yan Fu, Qianyan Long, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD
Jennifer Linge, Patrik Nasr, Arun J. Sanyal, et al.
JHEP Reports (2022) Vol. 5, Iss. 3, pp. 100663-100663
Open Access | Times Cited: 16
Functional Food Chemical Ingredient Strategies for Non-alcoholic Fatty Liver Disease (NAFLD) and Hepatic Fibrosis: Chemical Properties, Health Benefits, Action, and Application
Chong Yu, Xiaohe Guo, Xiaohang Cui, et al.
Current Nutrition Reports (2024) Vol. 13, Iss. 1, pp. 1-14
Closed Access | Times Cited: 3
Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
Myung Jin Kim, Yun Kyung Cho, Eun Hee Kim, et al.
Journal of Cachexia Sarcopenia and Muscle (2024) Vol. 15, Iss. 5, pp. 1942-1952
Open Access | Times Cited: 3
Assessing causal relationships between sarcopenia and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
Zehua Zhao, Juanjuan Zou, Xin Huang, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 14
Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis
Takumi Kawaguchi, Hirokazu Takahashi, Lynn H. Gerber
Clinics in Liver Disease (2023) Vol. 27, Iss. 2, pp. 275-286
Closed Access | Times Cited: 8
Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity
Eugene Han, Mi Kyung Kim, Hye Won Lee, et al.
Obesity (2022) Vol. 30, Iss. 12, pp. 2440-2449
Closed Access | Times Cited: 12
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma
Zhaoxian Li, Yumeng Zhao, Yan Xie, et al.
Hepatology International (2024) Vol. 18, Iss. 5, pp. 1516-1527
Closed Access | Times Cited: 2
Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
Camille Pichon, Maxime Nachit, Justine Gillard, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 11
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD
Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 3, pp. 322-333
Closed Access | Times Cited: 6
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong‐ho Lee
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 980-983
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top